Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc.（MLYS）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · MLYS · 截至 2026年6月8日
活动摘要
买入笔数
4
P-Purchase only
卖出笔数
74
近12个月
买卖比
0.05
Buy/Sell (by trades)
整体情绪
Mineralys Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
MLYS 季度内部人买卖趋势
MLYS 内幕交易卖出 · MLYS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · MLYS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
MLYS 高管卖出股份 · MLYS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 18, 2026 | Rodman David Malcom Chief Medical Officer | Option | 417 | $6K | Form 4 |
| May 18, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 417 | $11K | Form 4 |
| May 13, 2026 | Rodman David Malcom Chief Medical Officer | Option | 4,166 | $59K | Form 4 |
| May 12, 2026 | Rodman David Malcom Chief Medical Officer | Option | 6,348 | $7K | Form 4 |
| May 13, 2026 | Rodman David Malcom Chief Medical Officer | Option | 3,541 | $36K | Form 4 |
| May 11, 2026 | Rodman David Malcom Chief Medical Officer | Option | 2,171 | $35K | Form 4 |
| May 12, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 6,348 | $186K | Form 4 |
| May 11, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 2,171 | $65K | Form 4 |
| May 13, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 14,056 | $402K | Form 4 |
| Apr 17, 2026 | Rodman David Malcom Chief Medical Officer | Option | 416 | $6K | Form 4 |
| Apr 17, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 416 | $13K | Form 4 |
| Apr 13, 2026 | Rodman David Malcom Chief Medical Officer | Option | 4,167 | $59K | Form 4 |
| Apr 13, 2026 | Rodman David Malcom Chief Medical Officer | Option | 3,542 | $36K | Form 4 |
| Apr 13, 2026 | Rodman David Malcom Chief Medical Officer | Option | 6,349 | $7K | Form 4 |
| Apr 13, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 14,058 | $373K | Form 4 |
| Apr 15, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 6,348 | $176K | Form 4 |
| Apr 13, 2026 | Congleton Jon CEO · Director | Sale | 15,730 | $422K | Form 4 |
| Apr 9, 2026 | Rodman David Malcom Chief Medical Officer | Option | 2,170 | $35K | Form 4 |
| Apr 9, 2026 | Rodman David Malcom Chief Medical Officer | Sale | 2,170 | $59K | Form 4 |
| Mar 31, 2026 | Congleton Jon CEO · Director | Sale | 19,364 | $494K | Form 4 |
| Mar 31, 2026 | Congleton Jon CEO · Director | Sale | 55,183 | $1.46M⚡ | Form 4 |
| Mar 31, 2026 | Congleton Jon CEO · Director | Sale | 453 | $12K | Form 4 |
| Mar 31, 2026 | Karydas Daphne Director | Option | 3,000 | $36K | Form 4 |
| Mar 31, 2026 | Karydas Daphne Director | Sale | 3,000 | $75K | Form 4 |
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 58,300 | $1.41M⚡ | Form 4 |
RA CAPITAL MANAGEMENT, L.P.
Director
日期
Mar 30
股数
58,300
均价
$24.16
总金额
$1.41M ⚡
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 MLYS 内幕交易
MLYS 内幕交易
Mineralys Therapeutics, Inc.（MLYS）内幕交易数据来源于公司内部人（包括Rodman David Malcom (Chief Medical Officer), Congleton Jon (CEO · Director), Karydas Daphne (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。MLYS内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Mineralys Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
MLYS 内幕交易 · 5个问题Mineralys Therapeutics, Inc.（MLYS）的内部人包括高管和董事，如Rodman David Malcom (Chief Medical Officer), Congleton Jon (CEO · Director), Karydas Daphne (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026